Somewhat Positive Press Coverage Somewhat Unlikely to Impact Calithera Biosciences (CALA) Share Price
Media coverage about Calithera Biosciences (NASDAQ:CALA) has trended somewhat positive this week, according to Accern Sentiment Analysis. The research firm scores the sentiment of press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Calithera Biosciences earned a media sentiment score of 0.24 on Accern’s scale. Accern also gave news articles about the biotechnology company an impact score of 46.1714093493694 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near future.
These are some of the news articles that may have effected Accern’s analysis:
- 13G Filing: Adage Capital Management and Calithera Biosciences Inc. (CALA) (insidermonkey.com)
- Calithera Biosciences, Inc. (CALA) Major Shareholder Adage Capital Partners Gp, L.L Sells 576,000 Shares (americanbankingnews.com)
- Contrasting Calithera Biosciences (CALA) and Ardelyx (ARDX) (americanbankingnews.com)
- Calithera Biosciences : Appoints Blake Wise to Board of Directors (4-traders.com)
- Calithera Biosciences, Inc. (NASDAQ:CALA) Stock Traded Above Its 50 Day Moving Average – First News 24 (firstnewspaper24.com)
CALA has been the topic of a number of recent analyst reports. Zacks Investment Research raised shares of Calithera Biosciences from a “hold” rating to a “strong-buy” rating and set a $21.00 target price on the stock in a research report on Tuesday, July 11th. Wells Fargo & Company reaffirmed an “outperform” rating and issued a $20.00 target price (up from $15.00) on shares of Calithera Biosciences in a research report on Tuesday, June 6th. BidaskClub raised shares of Calithera Biosciences from a “hold” rating to a “buy” rating in a research report on Friday, July 7th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $19.00 target price (up from $14.00) on shares of Calithera Biosciences in a research report on Monday, June 12th. One analyst has rated the stock with a sell rating, two have assigned a hold rating and four have given a buy rating to the company. Calithera Biosciences currently has a consensus rating of “Hold” and an average price target of $15.50.
Shares of Calithera Biosciences (NASDAQ:CALA) traded up 0.96% on Friday, reaching $15.75. 508,997 shares of the company’s stock traded hands. The company has a 50 day moving average of $15.09 and a 200-day moving average of $14.12. Calithera Biosciences has a 52 week low of $2.20 and a 52 week high of $20.05. The stock’s market capitalization is $558.75 million.
Calithera Biosciences (NASDAQ:CALA) last posted its quarterly earnings results on Tuesday, August 8th. The biotechnology company reported ($0.15) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.14. The company had revenue of $7.26 million during the quarter, compared to analyst estimates of $4.80 million. Equities research analysts forecast that Calithera Biosciences will post ($0.83) earnings per share for the current year.
In other Calithera Biosciences news, major shareholder Adage Capital Partners Gp, L.L sold 576,000 shares of the business’s stock in a transaction on Thursday, September 28th. The shares were sold at an average price of $15.64, for a total transaction of $9,008,640.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Keith Orford sold 2,120 shares of the business’s stock in a transaction on Monday, July 17th. The shares were sold at an average price of $18.31, for a total transaction of $38,817.20. The disclosure for this sale can be found here. Insiders sold 578,820 shares of company stock worth $9,060,057 over the last ninety days. 16.30% of the stock is currently owned by corporate insiders.
ILLEGAL ACTIVITY WARNING: “Somewhat Positive Press Coverage Somewhat Unlikely to Impact Calithera Biosciences (CALA) Share Price” was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.thecerbatgem.com/2017/09/30/somewhat-positive-press-coverage-somewhat-unlikely-to-impact-calithera-biosciences-cala-share-price.html.
Calithera Biosciences Company Profile
Calithera Biosciences, Inc is a clinical-stage pharmaceutical company. The Company focuses on discovering and developing small molecule drugs directed against tumor and immune cell targets that control key metabolic pathways in the tumor microenvironment. It is engaged in developing agents that take advantage of the metabolic requirements of tumor cells and cancer-fighting immune cells, such as cytotoxic T-cells.
Receive News & Stock Ratings for Calithera Biosciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences Inc. and related stocks with our FREE daily email newsletter.